Abbvie to acquire Botox-maker – analysts and investors are skeptical
US drug group Abbvie celebrates its deal to buy Botox-manufacturer Allergan but analysts question the company's reasoning. The shareholders, who were not involved in the decision, punish the company with a 16 percent's decline in the share price.
A new giant in the medical industry is on the way after the acquisition deal between US drug group Abbvie and Irish-based Botox-maker Allergan.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
